Aarti Drugs Ltd. consolidated net profit grew 33% in the fourth quarter of the last financial year.
The pharmaceutical company posted a profit of Rs 63 crore in the quarter ended March, according to an exchange filing on Tuesday.
Aarti Drugs Q4 FY25 Highlights (Consolidated, YoY)
Revenue up 9% to Rs 676 crore versus Rs 620 crore.
Ebitda up 8% to Rs 93.2 crore versus Rs 86.1 crore.
Margin narrows to 13.8% versus 13.9%.
Net profit up 33% to Rs 63 crore versus Rs 47.4 crore.
Shares of Aarti Drugs closed 1.45% lower at Rs 349.9 apiece on the National Stock Exchange before the results were announced, compared to a 0.33% decline in the benchmark Nifty.
WRITTEN BY
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU

India's Direct Tax Collections Jump 9.18% To Rs 10.8 Lakh Crore Over Fewer Refunds


'Export-Focused Stocks May Jump': Market Veteran Bullish On THESE Sectors If US Tariff Declines

.jpg?rect=0%2C0%2C3500%2C1969&w=75)
JSW Cement Q1 Results: Net Loss Widens To Rs 1,356 Crore On Exceptional Expense


NMDC Steel Shares Jump Nearly 16% After Profitable Q1
